Gene therapy for hemophilia represents a groundbreaking advancement in treating this genetic disorder, particularly hemophilia B, where patients suffer from a deficiency of clotting factor IX.In February 2025, Terence Blue became the first individual in New England to receive Hemgenix, a pioneering gene therapy approved by the FDA in 2022, specifically designed to address the root cause of hemophilia.